Is the business good?
How good a business is COLL?
Collegium Pharmaceutical, Inc. keeps 24% of every revenue dollar as operating profit, against 12% for the median Drug Manufacturers - Specialty & Generic name.
24%
Operating margin · Drug Manufacturers - Specialty & Generic median 12% · 12 months to Q1 2026
- Share count, year on year
- +22%
Share count, year on year · shareholders own a smaller slice than a year ago
- Gross margin
- 61%
Gross margin
| Year | Operating margin |
|---|---|
| FY2020 | 18% |
| FY2021 | 6.4% |
| FY2022 | 7.2% |
| FY2023 | 29% |
| FY2024 | 27% |
| FY2025 | 23% |
Details›
- Gross margin12 months to Q1 2026
- 61%
- Operating margin12 months to Q1 2026
- 24%
- Net margin12 months to Q1 2026
- 9.4%
- Free cash flow margin
- 41%
- Revenue, trailing twelve months
- $796M
- Free cash flow, trailing twelve months
- $330M
- Net income, trailing twelve months
- $75M
Margins, capital and share counts from the statements as filed with the SEC; cash conversion from the cash flow statement.
Drug Manufacturers - Specialty & Generic
Ranks #13 of 28 by Smart Score